Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223229 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
A Phase 2 study of Non-segmental Vitiligo, sponsored by Elixiron Immunotherapeutics (Hong Kong).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT07223229: Recruiting Phase 2 study of Non-segmental Vitiligo, sponsored by Elixiron Immunotherapeutics (Hong Kong).
NCT07223229 is a Phase 2 study of Non-segmental Vitiligo that is actively recruiting participants, run by Elixiron Immunotherapeutics (Hong Kong). The registered enrollment target is 45 participants, below the 265-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223229, a Phase 2 study of Non-segmental Vitiligo, is actively recruiting participants, sponsored by Elixiron Immunotherapeutics (Hong Kong).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL EI-001
Study Locations (3)
Florida
- Skin Care Research, LLC - Hollywood
Massachusetts
- U Mass Chan Medical School Department of Dermatology - Worcester
Other
- Linkou Chang Gung Memorial Hospital - Taoyuan District
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What NCT07223229 shows while recruiting
NCT07223229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 265-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07223229 reports a single indexed study location in Florida, Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT07223229 about?
NCT07223229 is a clinical study titled "Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients". The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 hea...
What is the current status of trial NCT07223229?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-12-30. Estimated completion is 2027-09-30.
What conditions does trial NCT07223229 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT07223229?
The interventions under investigation include: Placebo (OTHER), EI-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07223229?
This trial is sponsored by Elixiron Immunotherapeutics (Hong Kong), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223229 being conducted?
This trial has 3 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07223229's enrollment target sits among peer trials
45 9th of 9 higher than 1 of 9 other Non-segmental Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-segmental Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI